Effects of itraconazole, dexamethasone and naringin on the pharmacokinetics of nadolol in rats

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 4, 2013, Pages 356-361

  Miyazaki, Nozomu ^a   Misaka, Shingen ^a   Ogata, Hiroshi ^a   Fukushima, Tetsuhito ^a   Kimura, Junko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Celiprolol; Dexamethasone; Itraconazole; Nadolol; Naringin; Oatp1a5; P gp

Indexed keywords

AURANTIIN; CELIPROLOL; DEXAMETHASONE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN; NADOLOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; ILEUM; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; URINE VOLUME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CELIPROLOL; DEXAMETHASONE; FLAVANONES; INTESTINAL ABSORPTION; ITRACONAZOLE; MALE; NADOLOL; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883187364     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-111     Document Type: Article

References (27)

1. Klaassen, C. D. and Aleksunes, L. M.: Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev., 62: 1-96 (2010).
2. Ho, R. H. and Kim, R. B.: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther., 78: 260-277 (2005).
3. Dumond, J. B., Vourvahis, M., Rezk, N. L., Patterson, K. B., Tien, H. C., White, N., Jennings, S. H., Choi, S. O., Li, J., Wagner, M. J., La-Beck, N. M., Drulak, M., Sabo, J. P., Castles, M. A., Macgregor, T. R. and Kashuba, A. D.: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin. Pharmacol. Ther., 87: 735-742 (2010).
4. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I.: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther., 66: 338-345 (1999).
5. Schwarz, U. I., Seemann, D., Oertel, R., Miehlke, S., Kuhlisch, E., Fromm, M. F., Kim, R. B., Bailey, D. G. and Kirch, W.: Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 77: 291-301 (2005).
6. Shirasaka, Y., Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P. and Tamai, I.: Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 332: 181-189 (2010).
7. Kodawara, T., Masuda, S., Wakasugi, H., Uwai, Y., Futami, T., Saito, H., Abe, T. and Inu, K.: Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res., 19: 738-743 (2002).
8. Bernsdorf, A., Giessmann, T., Modess, C., Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B. and Siegmund, W.: Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br. J. Clin. Pharmacol., 61: 440-450 (2006).
9. Ma, J. D., Tsunoda, S. M., Bertino, J. S., Jr., Trivedi, M., Beale, K. K. and Nafziger, A. N.: Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin. Pharmacokinet., 49: 223-237 (2010).
10. Oswald, S., Terhaag, B. and Siegmund, W.: In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal Pglycoprotein (ABCB1) in humans. Handb. Exp. Pharmacol., 201: 403-447 (2011).
11. Heel, R. C., Brogden, R. N., Pakes, G. E., Speight, T. M. and Avery, G. S.: Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs, 20: 1-23 (1980).
12. 14C] Nadolol in Rats. Jpn. Pharmacol. Ther., 12: 881-902 (1984).
13. Custodio, J. M., Wu, C. Y. and Benet, L. Z.: Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev., 60: 717-733 (2008).
14. Kato, Y., Miyazaki, T., Kano, T., Sugiura, T., Kubo, Y. and Tsuji, A.: Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci., 98: 2529-2539 (2009).
15. Terao, T., Hisanaga, E., Sai, Y., Tamai, I. and Tsuji, A.: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol., 48: 1083-1089 (1996).
16. Shirasaka, Y., Li, Y., Shibue, Y., Kuraoka, E., Spahn-Langguth, H., Kato, Y., Langguth, P. and Tamai, I.: Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm. Res., 26: 560-567 (2009).
17. Gupta, S., Kim, J. and Gollapudi, S.: Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J. Clin. Invest., 87: 1467-1469 (1991).
18. Lilja, J. J., Backman, J. T., Laitila, J., Luurila, H. and Neuvonen, P. J.: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther., 73: 192-198 (2003).
19. Zolnerciks, J. K., Booth-Genthe, C. L., Gupta, A., Harris, J. and Unadkat, J. D.: Substrate-and species-dependent inhibition of P-glycoproteinmediated transport: implications for predicting in vivo drug interactions. J. Pharm. Sci., 100: 3055-3061 (2011).
20. Micuda, S., Fuksa, L., Mundlova, L., Osterreicher, J., Mokry, J., Cermanova, J., Brcakova, E., Staud, F., Pokorna, P. and Martinkova, J.: Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly. Clin. Exp. Pharmacol. Physiol., 34: 296-303 (2007).
21. Kageyama, M., Fukushima, K., Togawa, T., Fujimoto, K., Taki, M., Nishimura, A., Ito, Y., Sugioka, N., Shibata, N. and Takada, K.: Relationship between excretion clearance of rhodamine 123 and Pglycoprotein (Pgp) expression induced by representative Pgp inducers. Biol. Pharm. Bull., 29: 779-784 (2006).
22. Lin, J. H., Chiba, M., Chen, I. W., Nishime, J. A., deLuna, F. A., Yamazaki, M. and Lin, Y. J.: Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction. Drug Metab. Dispos., 27: 1187-1193 (1999).
23. Wang, Z., Hamman, M. A., Huang, S. M., Lesko, L. J. and Hall, S. D.: Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther., 71: 414-420 (2002).
24. Yoshida, S., Yamada, K., Tamura, Y. and Yoshida, S.: Role of the renal nerve in glucocorticoid hypertension. Endocrinol. Jpn., 35: 877-884 (1988).
25. MacLean, C., Moenning, U., Reichel, A. and Fricker, G.: Regional absorption of fexofenadine in rat intestine. Eur. J. Pharm. Sci., 41: 670-674 (2010).
26. Shirasaka, Y., Suzuki, K., Nakanishi, T. and Tamai, I.: Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J. Pharm. Sci., 100: 3843-3853 (2011).
27. Misaka, S., Miyazaki, N., Yatabe, M. S., Ono, T., Shikama, Y., Fukushima, T. and Kimura, J.: Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. J. Clin. Pharmacol. (2013), in press, DOI: 10.1002/ jcph.95.